

The Association of Adherence with Health-Related Quality of Life by Age Group Among Patients with Epilepsy

Velez FF¹, Lee LK²

¹ Sunovion Pharmaceuticals Inc., Marlborough, MA, USA, ² Health Outcomes Practice, Kantar Health, Foster City, CA, USA

BACKGROUND

- Epilepsy is a chronic disorder of the brain, characterized by recurrent seizures.¹
- Active epilepsy affects an estimated 1.0% (2.3 million) of the US adult population.²
- Existing studies show that non-adherence to antiepileptic medications (AEDs) is associated with reduced seizure control, lower health-related quality of life (HRQoL), decreased productivity, and seizure-related job loss.³⁻⁴
- Although non-adherence to AEDs affects HRQoL, little is known about how age may influence this relationship among patients with epilepsy.

OBJECTIVE

- To examine the association between adherence and HRQoL by age group among patients with epilepsy. Additionally, patient demographics, health characteristics and epilepsy characteristics were examined as predictors of HRQoL by age group.

METHODS

Data source

- Data from the 2011 (N=75,000), 2012 (N=71,157), and 2013 (N=75,000) US National Health and Wellness Survey (NHWS) were analyzed.
- The NHWS is a self-administered, Internet-based questionnaire from a sample of adults (aged 18 or older).

Sample

- This sample included those who self-reported being treated with any AED type and/or Rx for epilepsy (Total N=1,126) and grouped as:
 - Under 55 years old with low/medium adherence (n=366)
 - Under 55 years old with complete adherence (n=377)
 - 55 years or older with low/medium adherence (n=114)
 - 55 years or older with complete adherence (n=269)

Measures

Potential predictors: demographics, health characteristics, and epilepsy characteristics

- Demographics: age, gender, race/ethnicity, education, household income, and insurance.
- Health characteristics: body mass index (BMI), smoking status, alcohol use, exercise behavior, and the Charlson comorbidity index (CCI).
- Epilepsy-specific characteristics: years since epilepsy diagnosis and whether on monotherapy (1 AED) or adjunctive therapy (2+ AEDs).

Adherence

- Medication adherence was assessed with the 8-item Morisky Medication Adherence Scale (MMAS; survey years 2012-2013) or the 4-item Morisky Medication Adherence Scale (survey year 2011).
- Only corresponding items between the 8-item and 4-item MMAS were used to compute adherence, which was coded as high (complete adherence; score=0) vs. low/medium (scores >0).

Health-related quality of life

- Component summary scores from the Medical Outcomes Study 36-Item Short Form Survey Instrument version 2 (SF-36v2; survey years 2012 and 2013) or SF-12v2 (survey year 2011) were calculated
 - The physical component summary (PCS) and the mental component summary (MCS); population norm=50 (SD=10).
- The items from the SF-36v2/SF-12v2 were also used to derive a health utility score, using the SF-6D algorithm.
 - The health utility score ranges from 0 (a health state equivalent to death) to 1 (a health state equivalent to perfect health).

Statistical analyses

Bivariate analyses

- One-way ANOVAs (for continuous variables) and chi-square tests (for categorical variables) were conducted comparing demographics and health characteristics (e.g., age, gender, CCI), and epilepsy characteristics (i.e., years diagnosed with epilepsy and monotherapy vs. adjunctive therapy) by age groups.
- Additionally, HRQoL (MCS, PCS, SF-6D health utilities) were compared by age and adherence groups.
- All multiple pairwise comparisons were conducted with t-tests (continuous variables) or z-tests of column proportions (categorical variables) and adjusted using the Bonferroni correction.

Multivariable analyses

- Separate generalized linear models (GLMs) for the two age groups (under 55 and 55 years and older) were used to predict MCS, PCS, and SF-6D health utilities by low/medium adherence (vs. complete adherence), controlling simultaneously for clinically meaningful predictors and all significant predictors in bivariate analyses.

Any two-sided p<0.05 was considered statistically significant.

RESULTS

Sample characteristics (Table 1)

- Mean age was 46.3 years old (SD=14.92); 47.7% female.
- A significantly higher proportion of patients under 55 (n=743) vs. 55 and older (n=383) had low/medium adherence (49.3% vs. 29.8%, p<0.001).
- Among patients under 55, a significantly smaller proportion of those aged 18 to <25, 25 to <35, and 35 to <45 had complete adherence than those 45 to <55 (42.1%, 44.8%, 47.5% vs. 63.9%, respectively, p<0.05).

HRQoL: unadjusted comparisons (Table 2)

- Among patients under age 55, those with low/medium adherence had lower MCS than those with complete adherence (means=40.92 vs. 44.02, p<0.05).
 - PCS, and health utilities did not differ by adherence among patients under age 55.
- MCS, PCS, and health utilities did not differ by adherence among patients aged 55 and older.

Table 1: Patient demographics, health characteristics, and epilepsy characteristics by age groups

	Age Groups							p-value
	Under 55 Years N=743		55 Years or Older N=383		Total N=1126			
	M / %	SD / N	M / %	SD / N	M / %	SD / N		
Age	37.61 _a	9.73	63.24 _b	6.11	46.33	14.92	<0.001	
Charlson Comorbidity Index (CCI)	0.92 _a	3.05	0.99 _a	1.38	0.94	2.60	0.674	
Years diagnosed with epilepsy	19.33 _a	13.41	34.37 _b	18.10	24.49	16.77	<0.001	
Gender							<0.001	
Female	51.5%	383	40.2%	154	47.7%	537		
Male	48.5%	360	59.8%	229	52.3%	589		
Race/Ethnicity							<0.001	
non-Hispanic white	70.4%	523	86.7%	332	75.9%	855		
non-Hispanic black	11.3%	84	6.3%	24	9.6%	108		
Hispanic	9.4%	70	2.9%	11	7.2%	81		
other	8.9%	66	4.2%	16	7.3%	82		
Do you currently have health insurance?							0.004	
Yes	83.7%	622	90.1%	345	85.9%	967		
No	16.3%	121	9.9%	38	14.1%	159		
BMI Category							0.001	
underweight	2.4%	18	2.6%	10	2.5%	28		
normal	34.5%	256	23.8%	91	30.8%	347		
overweight	27.1%	201	34.2%	131	29.5%	332		
obese	33.0%	245	38.1%	146	34.7%	391		
unknown	3.1%	23	1.3%	5	2.5%	28		
Smoking Status							<0.001	
Current	26.0%	193	19.1%	73	23.6%	266		
Former	20.5%	152	40.7%	156	27.4%	308		
Never Smoker	53.6%	398	40.2%	154	49.0%	552		
Drink Alcohol							<0.001	
No	44.8%	333	62.1%	238	50.7%	571		
Yes	55.2%	410	37.9%	145	49.3%	555		
Exercise 20+ minutes 1+ past month							<0.001	
0 times	37.0%	275	53.3%	204	42.5%	479		
1+ times	63.0%	468	46.7%	179	57.5%	647		
Therapy							0.797	
Monotherapy (1 AED)	65.8%	489	66.6%	255	66.1%	744		
Combo-therapy (2+)	34.2%	254	33.4%	128	33.9%	382		

Note: P-value column represents values from overall ANOVAs (continuous variables) or chi-square tests (categorical variables). Values in the same row not sharing the same subscript are significantly different at p<0.05 in t-tests (continuous variables) or z-tests of column proportions (categorical variables). Tests are adjusted for all pairwise comparisons using the Bonferroni correction. Abbreviations: M=Mean; SD=Standard Deviation; BMI=Body Mass Index.

Table 2: Health-related quality of life by age and adherence groups (unadjusted comparisons)

	Age and Adherence Groups										p-value
	<55 Low/Med Adherence N=366		<55 Complete Adherence N=377		55+ Low/Med Adherence N=114		55+ Complete Adherence N=269		Total N=1126		
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	
Mental Component Summary	40.92 _a	11.45	44.02 _b	12.18	46.40 _{b,c}	12.51	48.64 _c	11.51	44.36	12.17	<0.001
Physical Component Summary	47.27 _a	10.19	46.30 _a	10.71	44.33 _{a,b}	12.13	43.34 _b	11.80	45.71	11.06	<0.001
SF6D Health Utilities	0.65 _a	0.13	0.68 _{a,b}	0.16	0.67 _{a,b}	0.14	0.69 _b	0.15	0.67	0.15	0.012

Note: P-value column represents values from overall ANOVAs. Values in the same row not sharing the same subscript are significantly different at p<0.05 in t-tests. Tests are adjusted for all pairwise comparisons using the Bonferroni correction. Abbreviations: SD=Standard Deviation.

Predictors of HRQoL by age group (Table 3)

- For those under 55, low/medium vs. complete adherence predicted lower MCS (adjusted means: 41.15 vs. 43.84) and health utilities (adjusted means: 0.654 vs. 0.675; each p<0.05).
- In contrast, adherence did not predict MCS, PCS, or health utilities for those 55 and older.
- Relative to adherence, CCI and smoking status were consistently significant predictors of lower MCS, PCS, and health utilities for both age groups.
- Monotherapy was predictive of higher MCS for those aged 55 and older, and predictive of higher PCS for those under age 55.

Table 3: Significant predictors of health-related quality of life by age group (multivariable results)

	Under 55 Years Old					55 Years and Older				
	B	SE	95% Confidence Interval		p-value	B	SE	95% Confidence Interval		p-value
			Lower	Upper				Lower	Upper	
Mental Component Summary Score (MCS)										
Years diagnosed	0.15	0.03	0.09	0.21	<0.001	0.06	0.03	0.00	0.13	0.069
BMI: Obese	-3.38	1.03	-5.40	-1.36	0.001	-1.06	1.55	-4.11	1.99	0.495
CCI	-0.46	0.14	-0.73	-0.18	0.001	-1.31	0.45	-2.18	-0.44	0.003
Low/Med Adher	-2.64	0.83	-4.27	-1.01	0.002	-2.39	1.28	-4.90	0.13	0.063
Current smoker	-2.85	1.03	-4.87	-0.83	0.006	-4.10	1.80	-7.62	-0.58	0.022
Underweight	-6.86	2.74	-12.24	-1.48	0.012	-3.11	3.90	-10.76	4.55	0.426
Former smoker	2.71	1.09	0.57	4.85	0.013	-0.57	1.34	-3.20	2.05	0.668
Monotherapy	1.09	0.89	-0.65	2.83	0.220	2.92	1.27	0.44	5.40	0.021
Physical Component Summary Score (PCS)										
Current smoker	-5.11	0.88	-6.82	-3.39	<0.001	-2.83	1.56	-5.89	0.22	0.069
BMI: Obese	-4.49	0.87	-6.20	-2.78	<0.001	-4.41	1.35	-7.05	-1.77	0.001
CCI	-0.77	0.12	-1.00	-0.53	<0.001	-3.04	0.39	-3.79	-2.28	<0.001
Former smoker	-2.84	0.93	-4.65	-1.02	0.002	-2.49	1.16	-4.76	-0.21	0.032
Drink alcohol	2.21	0.75	0.74	3.69	0.003	2.99	1.09	0.86	5.11	0.006
Exercise 0x/month	-2.08	0.77	-3.59	-0.57	0.007	-4.54	1.05	-6.59	-2.49	<0.001
Monotherapy	1.49	0.75	0.01	2.97	0.049	-0.47	1.10	-2.63	1.68	0.667
Gender: Male	1.42	0.74	-0.02	2.86	0.054	3.10	1.05	1.04	5.15	0.003
Underweight	-3.71	2.33	-8.28	0.86	0.111	-6.68	3.39	-13.32	-0.03	0.049
BMI Unknown	-2.46	2.15	-6.68	1.76	0.253	-9.08	4.55	-18.00	-0.17	0.046
Years diagnosed	0.01	0.03	-0.04	0.07	0.694	0.09	0.03	0.03	0.15	0.003
SF-6D Health Utilities										
Current smoker	-0.063	0.013	-0.088	-0.038	<0.001	-0.069	0.020	-0.108	-0.029	0.001
BMI: Obese	-0.048	0.013	-0.073	-0.023	<0.001	-0.063	0.017	-0.097	-0.029	<0.001
CCI	-0.008	0.002	-0.011	-0.004	<0.001	-0.027	0.005	-0.037	-0.017	<0.001
Years diagnosed	0.001	0.000	0.001	0.002	0.001	0.001	0.000	0.000	0.002	0.005
Gender: Male	0.023	0.011	0.003	0.044	0.028	0.024	0.013	-0.002	0.051	0.072
Low/Med Adher	-0.020	0.010	-0.040	0.000	0.049	-0.022	0.014	-0.050	0.006	0.126
Underweight	-0.063	0.034	-0.128	0.003	0.061	-0.098	0.044	-0.183	-0.013	0.024
Exercise 0x/month	-0.017	0.011	-0.039	0.004	0.115	-0.043	0.013	-0.069	-0.016	0.002
Former smoker	-0.006	0.013	-0.032	0.020	0.653	-0.038	0.015	-0.067	-0.008	0.012
Drink alcohol	0.002	0.011	-0.019	0.023	0.848	0.030	0.014	0.003	0.057	0.031

Note: Generalized linear models with identity link functions were conducted. All predictors included: MMAS adherence (low/medium vs. complete), gender (male vs. female), ethnicity (non-Hispanic Black, Hispanic, other vs. non-Hispanic white), CCI, BMI (overweight, obese, unknown vs. normal weight), exercise (0 times per month vs. 1+ times per month), smoking status (former, current vs. never smoker), alcohol consumption (drink vs. don't drink), insurance (have vs. don't have), years diagnosed with epilepsy, and therapy (monotherapy vs. adjunctive therapy [2Rx+]).

LIMITATIONS

- Due to the self-reported design of the study, AED treatment and other data cannot be verified and data are subject to recall bias.
- Data are cross-sectional, causal explanations cannot be made.
- The epilepsy subpopulation may have been selectively underrepresented and may favor younger, healthier adults.

CONCLUSIONS

- In this retrospective analysis of a nationally representative survey, younger patients (<55 years old) had lower adherence to AEDs.
- For younger patients, lower adherence, smoking, obesity, greater comorbidity burden, and years since diagnosis of epilepsy are associated with poorer HRQoL (MCS and health utilities).
- Findings may be informative for clinicians deciding on treatments for younger patients as treatments that would garner higher adherence could potentially offer better HRQoL among this age group.

REFERENCES

- Epilepsy fact sheet. World Health Organization. <http://www.who.int/mediacentre/factsheets/fs999/en/>.
- Kobau R et al. MMWR. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6145a2.htm?s_cid=mm6145a2_w.
- Hovinga, et al. *Epilepsy & Behavior* 2008;13(2):316-322.
- Jones RM, et al. *Seizure* 2006;15(7):504-508.

DISCLOSURES

This study was funded by Sunovion Pharmaceuticals Inc.